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ABSTRACT 
Truncated Epstein-Barr virus (EBV) membrane antigen gp350/220 (EBV-MA) lacking the membrane anchor was expressed and 
secreted into the medium of recombinant Chinese hamster ovary cells that had been cultured in Plasmapur hollow-fibre modules using 
defined serum-free medium. The EBV-MA in the medium was concentrated by 70% (w/v) ammonium sulphate precipitation and 
subsequently purified by immunoaffinity chromatography using an anti-EBV-MA (EBV.OT6) monoclonal antibody (mAb) column. 
Adsorbed antigen was eluted with 3 M MgCl, in phosphate-buffered saline, concentrated by Mono Q anion-exchange chromatography 
and analysed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis, silver staining and Western blotting using EBV-positive 
serum and anti-EBV-MA specific mAbs. Monospecific polyclonal rabbit antibodies against the purified EBV-MA were raised and 
purified by protein G affinity chromatography. For the measurement of EBV-MA antigen levels a sandwich enzyme-linked immunosor- 
bent assay using rabbit polvclonal antibodies and a horseradish peroxidase-conjugated anti-MA mAb was developed having a detection 
level of lb ng/&. _ . 
INTRODUCTION 
The Epstein-Barr virus (EBV) is a human lym- 
photropic and immunomodulating herpes virus 
which causes infectious mononucleosis upon pri- 
mary infection in adults [l]. In addition, EBV is 
associated with a number of other human malig- 
nancies, e.g., nasopharyngeal carcinoma and Bur- 
kitt’s lymphoma. Another result of primary infec- 
tion is the presence in serum of antibodies to a num- 
ber of EBV antigens, some of which are maintained 
at constant levels throughout life. One possibility 
for affecting the course of the various EBV-associ- 
ated diseases is vaccination. At the moment the tar- 
get antigen for the development of an EBV vaccine 
is the EBV membrane antigen (EBV-MA) gp350/ 
220 complex [24], which is found both on the enve- 
lopes of viral particles [5] and on the surface of EBV 
producer cells. In addition, EBV-MA may be a use- 
ful antigen in diagnostic assays. 
EBV-MA consists of the glycoproteins gp350 and 
gp220 that are encoded by the same gene, which has 
been mapped to the BamHI L DNA fragment of 
the B95-8 genome [6]. The mRNA of gp220 arises 
by internal splicing of the mRNA of gp350 in such a 
manner that the same open reading frame (BLLFl) 
is maintained [6]. EBV-MA is important for virion 
binding to human B lymphocytes via its specific in- 
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teraction with the complement receptor 2 (CR2) [7] 
and is also an efficient activator of the alternative 
pathway of complement [8]. The gp350 primary se- 
quence consists of 907 amino acids and includes 36 
potential signals for N-linked glycosylation, a single 
hydrophobic transmembrane domain and a short 
C-terminal domain. More than half of the relative 
molecular mass (M,) is contributed by glycosyl res- 
idues. EBV-MA is synthesized in the endoplasmic 
reticulum, undergoes rapid cotranslational N-link- 
ed glycosylation and is transported to the Golgi, 
where high-mannose N-linked oligosaccharides are 
trimmed and complex N- and O-linked oligosac- 
charides are added [9- 131. 
Several monoclonal antibodies (mAbs) against 
EBV-MA have been prepared and it has been re- 
ported by different groups that such antibodies me- 
diate virus neutralization, antibody-dependent cel- 
lular cytotoxicity, complement-dependent cytotox- 
icity and inhibition of virus release [14-181. It 
should be emphasized that the different epitopes of 
the EBV-MA complex play variable roles in virus 
neutralization, virus binding to target cell receptors 
and virus penetration [19]. Recent data suggest that 
only one epitope, located in the N-terminal region 
of EBV-MA, is involved in EBV neutralization and 
binding to target cell receptors [9,20]. 
Production of native EBV-MA for vaccination or 
diagnostic purposes is hampered by the lack of a 
suitable high-level expression system [3,4]. Recom- 
binant EBV-MA has been produced in bacteria 
[21], yeast [22], mouse L cells [29], rat pituitary GH3 
cells [23], Vero cells [23] and Chinese hamster ovary 
(CHO) cells [24] and has been expressed via differ- 
ent viral vectors [3,25,26]. Although cell-specific 
post-translational modifications critically influence 
the antigenic presentation of EBV-MA, all mam- 
malian cell-derived versions of EBV-MA were 
found capable of inducing EBV-specific neutraliz- 
ing antibodies [2]. As expressing levels of recombi- 
nant EBV-MA were low, suggesting that the pro- 
tein is toxic for eukaryotic cells, truncated forms of 
EBV-MA lacking the membrane anchor have been 
expressed [2,27,28]. Truncated EBV-MA was se- 
creted into the medium of transformed cells in cul- 
ture. Determination of truncated EBV-MA secre- 
tion was difficult and for CHO cells has been esti- 
mated from Coomassie Brilliant Blue-stained gels 
to be in the range l-10 pg per IO6 cells per day [28]. 
In this paper we describe the culturing and puri- 
fication of recombinant truncated EBV-MA from 
CHO cells [28] by mAb-based affinity chromatogra- 
phy and the subsequent development of an enzyme- 
linked immunosorbent assay (ELISA) procedure 
for the measurement of EBV-MA antigen levels. 
EXPERIMENTAL 
Muterids 
Protein G-Sepharose FF, a Mono Q column and 
cyanogenbromide-activated Sepharose were ob- 
tained from Pharmacia LKB Biotechnology (Upp- 
sala, Sweden). Prestained molecular mass markers 
and N,N’-diallyltartardiamide (DATD) were ob- 
tained from Bio-Rad Labs. (Richmond. CA, USA). 
All culture plastics were obtained from Costar 
(Badhoevedorp, Netherlands). Culture media were 
based on HAM’s FIZ--Dulbecco’s modified Eagle’s 
medium (DMEM) (1:1) from Gibco (Paisley, UK) 
and were occasionally supplemented with 10% foe- 
tal calf serum (Bocknek, Canada). Plasmapur hol- 
low-fibre modules and bovine serum albumin 
(BSA) were from Organon Teknika (Boxtel, Neth- 
erlands). Horseradish peroxidase (HRP) was pur- 
chased from Sigma (St. Louis, MO, USA). All other 
chemicals were of the highest grade available. 
Antibodies 
Polyclonal antibodies against EBV-MA were ob- 
tained from rabbits by multiple subcutaneous in- 
jections of 0.2 mg of purified EBV-MA in Freund’s 
complete adjuvant and after 2, 4 and 6 weeks they 
were boosted with the same amount of antigen in 
incomplete adjuvant. Anti-EBV-MA specific mAbs 
(EBV.OT2, -3. -6 and -7) were prepared as will be 
described elsewhere. MAb EBV.OTlC was gener- 
ously provided by Dr. D. Thorley-Lawson. Hybrid- 
omas were cultured in serum-free medium using 
Plasmapur hollow-fibre bioreactors [29]. Superna- 
tants from the extra-capillary compartment were 
harvested, centrifuged, divided into aliquots and 
stored at - 20°C. The total mouse immunoglobulin 
G (IgG) concentration in samples of hybridoma 
cultures was determined using the Sol Particle Im- 
munoassay [30]. IgGs were isolated on protein G- 
Sepharose FF according to the instructions of the 
manufacturer. The concentration of the purified 
monoclonal antibodies was determined by measur- 
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ing the absorbance at 280 nm using a molar absorp- 
tivity (l%, 1 cm) of 14.3 [31]. 
Human sera 
EBV-seropositive sera were obtained from 
healthy laboratory volunteers and commercial 
blood donor populations. Sera from acutely infect- 
ed patients were provided by Dr. G. Weers-Pothof 
(Department of Medical Microbiology, University 
Hospital, Nijmegen, Netherlands). 
PuriJication of EB V-MA 
Culturing of CHO cells secreting truncated EBV- 
MA was performed in roller bottles under metho- 
trexate selection [28]. When the cells were in the 
logarithmic phase they were inoculated in the extra- 
capillary compartment of hollow-fibre bioreactors 
and cultured without methotrexate essentially as 
described above for the hybridomas [29]. 
The EBV-MA in the extra-capillary harvest fluid 
of the CHO cells was precipitated with 70% (w/v) 
ammonium sulphate and dissolved in phosphate- 
buffered saline (PBS) (pH 7.4) and dialysed against 
the same buffer. Then EBV-MA was purified by 
monoclonal anti-EBV-MA antibody affinity chro- 
matography. For this mAb EBV.OT6 was coupled 
to cyanogen bromide-activated Sepharose 4B (10 
mg/ml) according to the manufacturer’s instruc- 
tions, and the gel was packed into a column (15 x 1 
cm I.D.). EBV-MA-containing dialysate was passed 
through a Millex-HA 0.22-pm filter (Millipore) and 
subsequently applied to the column, which had 
been equilibrated in PBS (pH 7.4) (10 ml/h). After 
extensive washing with the equilibration buffer, ad- 
sorbed EBV-MA was eluted with 3 M MgCl* in 
PBS (pH 7.4). The eluted protein fractions were 
pooled and dialysed against 50 mM Tris-HCl-50 
mM NaCl (pH 7.4). Concentration of EBV-MA 
and removal of traces of IgG leakage from the affin- 
ity matrix was performed with Mono Q anion-ex- 
change chromatography using fast protein liquid 
chromatographic (FPLC) equipment (Pharmacia) 
with a linear gradient of NaCl (50-500 mM NaCl, 
20 ml) with a flow-rate of 60 ml/h and a fraction size 
of 1 ml. Protein concentrations were determined by 
the bicinchoninic acid (BCA) protein assay (Pierce, 
Rockford, IL, USA) using BSA as reference. 
Electrophoretic and immunochemical techniques 
Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) was performed under 
non-reducing and reducing conditions on 6% slab 
gels with DATD as cross-linker using the Mini-Pro- 
tean II system (Bio-Rad Labs.) or on 415% gra- 
dient gels using the Phast system (Pharmacia) essen- 
tially according to Laemmli [32]. After electropho- 
resis, proteins were transferred to Immobilon mem- 
branes (Millipore) essentially as described [33]. The 
membranes were blocked with 5% (v/v) horse se- 
rum, 4% (w/v) non-fat dry milk [34] in PBS, in- 
cubated with monoclonal or polyclonal antibodies 
against EBV-MA and visualized with peroxidase- 
conjugated antiserum using 4-chloro-1-naphthol as 
substrate. 
The gels were stained with Coomassie Brilliant 
Blue R-250 or with an ammonical silver staining 
procedure essentially according to Morrisey [35]. 
Reduction was performed by incubating the sam- 
ples for 5 min at 90°C with 5% (v/v) 2-mercaptoeth- 
anol-10 mM Tris-HCl-2% (w/v) SDS-0.01% (w/ 
v) bromophenol blue-10% (v/v) glycerol (pH 6.8). 
ELISA for the measurement of EBV-MA 
A two-stage ELISA was developed using poly- 
clonal anti-EBV-MA IgG and an HRP-conjugated 
anti-EBV-MA mAb. Purified polyclonal anti-EBV- 
MA antibodies (5 pg/ml, 50 mM NaHC03, pH 9.6) 
were coated overnight on 96-well microtitre plates 
(Greiner) at 4°C. After removal of unbound EBV- 
MA antibodies by washing with PBS-Tween-20, 
the plates were blocked with 3% (w/v) BSA in PBS 
for 30 min and subsequently incubated with dilu- 
tions of purified EBV-MA [in 5% (v/v) normal goat 
serum-0.05% (v/v) Tween-20 in PBS] at room tem- 
perature for 2 h. After washing, HRP-conjugated 
mAb (EBV.OT6) was applied and incubated for 1 
h. Bound conjugated antibody was developed for 
peroxidase activity using the substrate 3,3’, 5,5’-tet- 
ramethylbenzidine. The absorbance at 450 nm was 
read against a blank using an Anthos 2001 reader. 
MAb EBV.OT6 was conjugated with HRP (Type 
VI) (Sigma) by periodate oxidation. 
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RESULTS 
Characterization qf monoclorlal antihodie.~ uguinst 
EBV-MA 
For the development of an EBV-MA specific im- 
munoaffinity purification process, five mouse mAbs 
against EBV-MA were obtained and characterized 
by Western blotting and ELTSA. The mAbs 
EBV.OTlC and EBV.OT6 demonstrated a strong 
positive reactivity with EBV-MA in ELISA (Fig. 1). 
whereas the mAb’s EBV.OT 2, 3 and 7 showed mi- 
nor reactivity. As only mAb EBV.OT6 was reactive 
in Western blotting (Fig. 2) this mAb was selected 
for purification purposes. 
Purification qf EBV-MA 
Recombinant truncated EBV-MA secreting 
CHO cells were cultured in Plasmapur hollow-fibre 
modules using defined serum-free medium. Fig. 3 
shows a Western blot analysis of supernatants de- 
rived from the cell line at several days of culture 
using an anti-EBV positive human serum. Owing to 
extensive glycosylation EBV-MA appears as diffuse 
bands. 
The EBV-MA was purified from the medium of 
CHO cells by ammonium sulphate precipitation, 
monoclonal anti-EBV-MA antibody affinity and 
Mono Q anion-exchange chromatography (not 
shown), and subsequently analysed by SDS-PAGE 
Fig. 2. Western blot analysis of the reactivity of diiferrnt anti- 
EBV-MA m,\bs vcith recombinant EBV-MA. EBV-MA was 
subjected to 6% SDS-PAGE and the gels vvere transferred to 
Immobilon membranes. The membranes \\crc incubated with 
the mAhs and visual&d with pel-ozidasc-cotljugatcd antiserum. 
A/I, standards (kilodaltons) and a positive control (C) with EBV- 
positive human serum are Includell. 
and Western blotting. The purified EBV-MA dem- 
onstrated a characteristic doublet of gp350 and 
gp220 on a silver-stained SDS- polyacrylamide 
(PAA) slab gel and was devoid of low-M, contami- 
nants (Fig. 4a). Reduced and non-reduced purified 
EBV-MA showed similar electrophoretic mobilities 
(not shown). Fig. 4b shows the positive reactivity of 
the purified EBV-MA with the HRP-labelled anti- 
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Fig. I. Reactivity of mAbs with recombinant truncated EBV- : ::::,: : : 
MA. The binding activities of (2) mAb EBV.OTlC, (L) -2, (CL’) 
-3, ( n ) -6 and (CA’) -7 to recombinant EBV-MA were determined Fig. 3. Western blot analysis of culture supernatants from CHO 
by ELISA. Microtitre wells were coated with 1:lOO dilutions of cells secreting truncated EBV-MA [XI. Culture supcrnatants 
ammonium sulphate-concentrated EBV-MA preparations and from subsequent passages were run on a 6% SDS-PAA gel and 
incubated with various concentrations of each mAb. Bound anti- transferred to Immohilon mrmhrancs. ‘The mcmhrancs wcrc de- 
body was detected with peroxidase-conjugated sheep anti-mouse velopcd with a I:1000 dilution of an anti-EBV positive human 
IgCr and 3.3’,5,5’-tetramethylhcnzidine. strum and HRP-labelled anti-human antiserum. 
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Fig. 4. SDS-PAGE of immunopurified recombinant EBV-MA 
visualized by (A) silver staining and (B) immunoblotting. Re- 
duced EBV-MA was subjected to 6% SDS-PAGE and the gels 
were stained with silver or transferred to Immobilon membranes. 
The membranes were incubated with the mAb EBV.OT6 (lane 1) 
or human serum (lane 2) and visualized with peroxidase-conju- 
gated antiserum. iM, standards are indicated (kilodalton). 
EBV-MA mAb EBV.OT6 and an EBV-positive hu- 
man serum in Western blotting analysis. 
ELISA for EBV-MA 
A two-stage EBV-MA ELISA was developed us- 
ing immunopurified polyclonal anti-EBV-MA IgG, 
coated to 96-well microtitre plates, in the solid 
phase and peroxidase-conjugated monoclonal anti- 
EBV-MA IgG in the liquid phase. Fig. 5 shows a 
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Fig. 5. Dose-response curve of serially diluted EBV-MA in EL- 
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Fig. 6. Long-term cultivation of CHO cells secreting truncated 
EBV-MA in hollow-fibre modules. Monitoring of EBV-MA pro- 
duction was performed during the culture period as measured by 
ELISA. 
representative dose-response curve for the EBV- 
MA ELISA. A significant difference in absorbance 
as compared with buffer alone corresponded to a 
detection limit of about 10 ng/ml. 
The EBV-MA production during the cell culture 
period of the CHO cells was monitored by this pro- 
cedure, as shown in Fig. 6. Starting at day 0 a con- 
centration of 9.3 pg/ml of EBV-MA (in roller bottle 
culture) was obtained. The concentration of EBV- 
MA in the medium of the hollow-fibre modules in- 
creased slowly up to 20 days, followed by a period 
of decline. This decline was caused by the change of 
the culture in the extra-capillary compartment to a 
serum-free medium. Subsequently, a period of ex- 
ponential increase of EBV-MA production was ob- 
served that reached its maximum (150 pg/ml) at day 
50 which was followed by a period of decline until 
the end of the culture. 
DISCUSSION 
Truncated recombinant EBV-MA derived from 
CHO cells was purified by ammonium sulphate pre- 
cipitation and anti-EBV-MA mAb affinity and 
anion exchange chromatography. Both gp350 and 
gp220 species were obtained, which is in agreement 
with previously reported results [24,28]. The observ- 
ed M, values suggest a close to natural glycosyla- 
tion, which is relevant for vaccination purposes 
[24]. However, the nature of the N- and O-linked 
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oligosaccharides attached to the recombinant EBV- 
MA remains to be characterized. The recombinant 
CHO cell line showed stable production character- 
istics over several weeks under serum-free culture 
conditions without methotrexate selection. No dra- 
matic changes were observed in either production 
level (about 75 @g/ml per day) or the nature of the 
protein species produced. Hence the procedure de- 
scribed in this paper allows for the development ofa 
simple, ethcient and economical system for the 
large-scale production of EBV-MA. 
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